Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + CLAG-M in AML and High-Grade Myeloid Neoplasms
NCT04797767Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Feb 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), myeloid neoplasm, mixed phenotype acute leukemia (MPAL) and 1 more, sponsored by University of Washington. Primary endpoints: Incidence of adverse events at 12 months, Maximum tolerated dose of venetoclax in combination with CLAG-M at 12 months and 1 more. Started Feb 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myeloid neoplasmmixed phenotype acute leukemia (MPAL)myeloid sarcoma (MS)
Beyond the preview
Go deeper on NCT04797767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797767.